Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA.
Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.
World J Urol. 2021 Sep;39(9):3359-3365. doi: 10.1007/s00345-021-03650-4. Epub 2021 Mar 29.
Cytoreductive nephrectomy (CN) benefits a subset of patients with metastatic renal cell carcinoma (mRCC), however proper patient selection remains complex and controversial. We aim to characterize urologists' reasons for not undertaking a CN at a quaternary cancer center.
Consecutive patients with mRCC referred to MSKCC urologists for consideration of CN between 2009 and 2019 were included. Baseline clinicopathologic characteristics were used to compare patients selected or rejected for CN. The reasons cited for not operating and the alternative management strategies recommended were extrapolated. Using an iterative thematic analysis, a framework of reasons for rejecting CN was designed. Kaplan-Meier estimates tested for associations between the reasons for not undertaking a CN and overall survival (OS).
Of 297 patients with biopsy-proven mRCC, 217 (73%) underwent CN and 80 (27%) did not. Median follow-up of patients alive at data cut-off was 27.3 months. Non-operative patients were older (p = 0.014), had more sites of metastases (p = 0.008), harbored non-clear cell histology (p = 0.014) and reduced performance status (p < 0.001). The framework comprised seven distinct themes for recommending non-operative management: two patient-fitness considerations and five oncological considerations. These considerations were associated with OS; four of the oncological factors conferred a median OS of less than 12 months (p < 0.001).
We developed a framework of criteria by which patients were deemed unsuitable candidates for CN. These new insights provide a novel perspective on surgical selection, could potentially be applicable to other malignancies and possibly have prognostic implications.
细胞减灭性肾切除术(CN)使一部分转移性肾细胞癌(mRCC)患者受益,但合适的患者选择仍然复杂且存在争议。我们旨在描述一家四级癌症中心的泌尿科医生不进行 CN 的原因。
连续纳入 2009 年至 2019 年期间在 MSKCC 泌尿科医生处考虑进行 CN 的 mRCC 患者。比较选择或拒绝 CN 的患者的基线临床病理特征。推断出未手术的原因和推荐的替代治疗策略。使用迭代主题分析,设计了拒绝 CN 的原因框架。Kaplan-Meier 估计检验了不进行 CN 的原因与总生存(OS)之间的关联。
在 297 例经活检证实的 mRCC 患者中,217 例(73%)接受了 CN,80 例(27%)未接受。截止数据截止时存活患者的中位随访时间为 27.3 个月。非手术患者年龄较大(p=0.014),转移部位较多(p=0.008),存在非透明细胞组织学(p=0.014)和较低的体能状态(p<0.001)。该框架包含了推荐非手术治疗的七个不同主题:两个患者健康状况考虑因素和五个肿瘤学考虑因素。这些考虑因素与 OS 相关;其中四个肿瘤学因素的中位 OS 小于 12 个月(p<0.001)。
我们制定了一个框架,根据该框架,患者被认为不适合进行 CN。这些新的见解为手术选择提供了新的视角,可能适用于其他恶性肿瘤,并可能具有预后意义。